- Lobbying
- Lobbying by Shire Pharmaceuticals
Lobbying Relationship
Bills mentioned
H.R.1548: Pathway for Biosimilars Act
Sponsor: Anna G. Eshoo (D-Calif.)
H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act
Sponsor: Henry A. Waxman (D-Calif.)
H.R.5629: Pathway for Biosimilars Act
Sponsor: Anna G. Eshoo (D-Calif.)
H.R.1634: Newborn Screening Saves Lives Act of 2007
Sponsor: Lucille Roybal-Allard (D-Calif.)
S.634: Newborn Screening Saves Lives Act of 2007
Sponsor: Christopher J. Dodd (D-Conn.)
S.1858: Newborn Screening Saves Lives Act of 2007
Sponsor: Christopher J. Dodd (D-Conn.)
H.R.3825: Newborn Screening Saves Lives Act of 2008
Sponsor: Lucille Roybal-Allard (D-Calif.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Michael Werner | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate